Tropical diseases encompass all diseases that occur solely, or principally, in the tropics. In practice, the term is often taken to refer to infectious diseases that thrive in hot, humid conditions, such as malaria, leishmaniasis, schistosomiasis, onchocerciasis, lymphatic filariasis, Chagas disease, African trypanosomiasis, and dengue.
If an infectious disease outbreak or an attack using an agent such as anthrax were to occur in Chicago, it most likely first will be noticed in emergency rooms throughout the city. Swift identification of the cause of an incoming patients' illness could be crucial to public health and safety personnel being able to intervene in time to save lives.
Wellcome Trust Sanger Institute scientists show how the parasite responsible for the neglected tropical disease Black Fever (visceral leishmaniasis) can become resistant to drug treatment. Studying the whole genomes of more than 200 samples of Leishmania donovani revealed that the addition of just two bases of DNA to a gene known as LdAQP1 stops the parasite from absorbing antimonial drugs.
For the first time, genome sequencing has been carried out on Chlamydia trachomatis (C. trachomatis), a bacteria responsible for the disease Trachoma - the world's leading infectious cause of blindness, according to a study in Nature Communications.
The world's first vaccine for a disease that causes misery for millions in Africa could be tested within five years.
Researchers at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego have entered into a research collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to identify new therapeutic targets for Chagas disease, a parasitic infection that is the leading cause of heart failure in Latin America.
Treating multidrug-resistant tuberculosis (MDR TB) with regimens that include a greater number of drugs may improve outcomes, and baseline drug susceptibility testing (DST) could identify drugs with the greatest likelihood of success, according to a paper published this week in PLOS Medicine.
Despite the increasing risks of mosquito-transmitted epidemics in the United States and Mexico, policymakers in both countries have made little effort to prevent future outbreaks, according to a new policy brief by tropical-disease and science policy experts at Rice University's Baker Institute for Public Policy.
Researchers from Spain have analysed the prevalence of leishmaniasis among the population of organ transplant recipients. The findings of this study, published in the journal 'PLoS Neglected Tropical Disease', confirm that the risk of developing visceral leishmaniasis ‑the most severe form of the disease which can pose life-threatening complications‑ is more than one hundred times greater in transplant patients living in areas of disease outbreak.
Chagas disease -- the third most common parasitic infection in the world -- affects approximately 7.5 million people, mostly in Latin America. To help reduce outbreaks of this disease in their countries, the United States and Mexican governments should implement a range of programs as well as fund research for the development of Chagas vaccines and treatments, according to a new policy brief by tropical-disease and science policy experts at Rice University's Baker Institute for Public Policy.
Snakebite claims thousands of lives in the world's poorest communities every year but remains a 'forgotten killer,' according to a new editorial published in the British Medical Journal.
Dengue is a mosquito-borne tropical disease currently endemic in more than 10 countries. According to the World Health Organization, 390 million people are infected by dengue every year.
An international research team, headed by Joseph Vinetz, MD, professor of medicine at University of California, San Diego School of Medicine and director of the UC San Diego Center for Tropical Medicine and Travelers Health, has been awarded a 5-year, $1.89 million cooperative agreement to carry out translational research studies of leptospirosis, an infectious and sometimes fatal bacterial disease endemic in much of the world.
In a special free issue of Future Medicinal Chemistry, leading experts explore current and potential new treatment options for the deadly neglected tropical disease schistosomiasis.
The National Center for Advancing Translational Sciences, part of the National Institutes of Health (NIH), has awarded James McKerrow, MD, PhD, director of the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, with a 2015 New Therapeutic Uses Award.
A new article in Clinical Investigation highlights the learnings gleaned from monitoring several complex HIV clinical trials in Africa over a 15 year period.
The team has completed two genomics studies on the tropical disease, a condition that is estimated to cause up to 30 million illnesses and over a quarter of a million deaths globally each year.
Insects, such as mosquitoes and ticks, are responsible for transmitting a range of diseases, such as malaria, chikungunya, dengue fever, and West Nile virus. The risk of contracting such illnesses is generally only considered when booking an exotic holiday. However, experts from the Emergency Response Department at Public Health England have warned that climate change could allow such vector-borne diseases to emerge closer to home.
Half a century ago, a concentrated global effort nearly wiped a disfiguring tropical disease from the face of the earth. Now, says Case Western Reserve's James W. Kazura, MD, it's time to complete the work.
In an advance that may potentially lead to new treatments for parasitic hookworms, scientists at the University of Massachusetts Medical School and Cornell University have sequenced the genome of the hookworm, Ancylostoma ceylanicum.
WHO urges affected countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low and middle income countries for the period 2015-2030.